Literature DB >> 8028019

Titin, myosin light chains and C-protein in the developing and failing human heart.

I Morano1, K Hädicke, S Grom, A Koch, R H Schwinger, M Böhm, S Bartel, E Erdmann, E G Krause.   

Abstract

We investigated relative amounts of titin, myosin light chains (MLC), C-protein, and myosin heavy chains (MHC) in the functionally intact contractile apparatus of embryonic, adult normal, and adult failing human left ventricle by SDS polyacrylamide gel electrophoresis and Western blot analysis. The amount of titin and the titin-MHC ratio was significantly (P < 0.05) lower in the embryonic and adult failing human compared to the adult normal fibres. Additionally, we found a protein band having a lower molecular weight but the same immunoreactivity as native titin (fast-migrating titin; FM-titin) in the failing heart only. The MLC-1/MLC-2 ratio was about 1.0 in normal and failing hearts but about 2.0 in the embryonic heart. Relative amount of C-protein was the same in normal and failing fibres but lower in the embryonic ventricles. Length-tension ratio of chemically skinned fibres prepared from terminally failing hearts was impaired compared to normal heart fibres. We conclude that both the reduced titin/MHC ratio and the expression of a structurally different titin form may be involved in the impaired contractile function of the terminally failing human heart.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028019     DOI: 10.1006/jmcc.1994.1045

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  19 in total

1.  Right ventricular pressure and dilation during pressure overload determine dysfunction after pressure overload.

Authors:  C Greyson; Y Xu; L Lu; G G Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-05       Impact factor: 4.733

2.  Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation.

Authors:  M R Wolff; S H Buck; S W Stoker; M L Greaser; R M Mentzer
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

4.  Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Authors:  Mohammad A M Ali; Woo Jung Cho; Bryan Hudson; Zamaneh Kassiri; Henk Granzier; Richard Schulz
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

Review 5.  Titin: physiological function and role in cardiomyopathy and failure.

Authors:  Henk Granzier; Yiming Wu; Labeit Siegfried; Martin LeWinter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

Review 6.  Thick filament proteins and performance in human heart failure.

Authors:  Bradley M Palmer
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

7.  Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.

Authors:  S Bartel; B Stein; T Eschenhagen; U Mende; J Neumann; W Schmitz; E G Krause; P Karczewski; H Scholz
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 8.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

9.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart.

Authors:  W K Jones; I L Grupp; T Doetschman; G Grupp; H Osinska; T E Hewett; G Boivin; J Gulick; W A Ng; J Robbins
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

10.  Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments.

Authors:  H L Granzier; T C Irving
Journal:  Biophys J       Date:  1995-03       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.